Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes

被引:0
|
作者
Ayelet Kaminitz
Shifra Ash
Nadir Askenasy
机构
[1] The Leah and Edward M. Frankel Laboratory of Experimental Bone Marrow Transplantation,
关键词
Type 1 diabetes; Autoimmunity; Inflammatory insulitis; Proinflammatory cytokines; β-cell death; Immune homeostasis; Regulatory T cells;
D O I
暂无
中图分类号
学科分类号
摘要
As physiological pathways of intercellular communication produced by all cells, cytokines are involved in the pathogenesis of inflammatory insulitis as well as pivotal mediators of immune homeostasis. Proinflammatory cytokines including interleukins, interferons, transforming growth factor-β, tumor necrosis factor-α, and nitric oxide promote destructive insulitis in type 1 diabetes through amplification of the autoimmune reaction, direct toxicity to β-cells, and sensitization of islets to apoptosis. The concept that neutralization of cytokines may be of therapeutic benefit has been tested in few clinical studies, which fell short of inducing sustained remission or achieving disease arrest. Therapeutic failure is explained by the redundant activities of individual cytokines and their combinations, which are rather dispensable in the process of destructive insulitis because other cytolytic pathways efficiently compensate their deficiency. Proinflammatory cytokines are less redundant in regulation of the inflammatory reaction, displaying protective effects through restriction of effector cell activity, reinforcement of suppressor cell function, and participation in islet recovery from injury. Our analysis suggests that the role of cytokines in immune homeostasis overrides their contribution to β-cell death and may be used as potent immunomodulatory agents for therapeutic purposes rather than neutralized.
引用
收藏
页码:460 / 472
页数:12
相关论文
共 50 条
  • [41] Possible involvement of autoimmunity in fulminant type 1 diabetes
    Oikawa, Yoichi
    Shimada, Akira
    DIABETOLOGY INTERNATIONAL, 2020, 11 (04) : 329 - 335
  • [42] Autoimmunity to tetraspanin-7 in type 1 diabetes
    McLaughlin, Kerry A.
    Tombs, Melissa A.
    Christie, Michael R.
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2020, 209 (04) : 437 - 445
  • [43] Monocytes from Patients with Type 1 Diabetes Spontaneously Secrete Proinflammatory Cytokines Inducing Th17 Cells
    Bradshaw, Elizabeth M.
    Raddassi, Khadir
    Elyaman, Wassim
    Orban, Tihamer
    Gottlieb, Peter A.
    Kent, Sally C.
    Hafler, David A.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (07): : 4432 - 4439
  • [44] The environment and the origins of islet autoimmunity and Type 1 diabetes
    Regnell, S. Eringsmark
    Lernmark, A.
    DIABETIC MEDICINE, 2013, 30 (02) : 155 - 160
  • [45] Characterization of Autoimmunity in the Acceleration of Atherosclerosis in Type 1 Diabetes
    Park, Kyoungmin
    Li, Qian
    Park, Hyunseok
    St-Louis, Ronald
    Fu, Jialin
    Rask-Madsen, Christian
    Maddaloni, Ernesto
    Yokomizo, Hisashi
    Kissler, Stephan
    Lichtman, Andrew H.
    King, George L.
    DIABETES, 2020, 69
  • [46] Gastric motility and gastric autoimmunity in type 1 diabetes
    De Block, C
    De Leeuw, T
    Pelckmans, P
    Callens, D
    Van Acker, K
    Peiffer, F
    Van Gaal, L
    DIABETES, 2001, 50 : A93 - A93
  • [47] Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes
    Kroger, Charles J.
    Clark, Matthew
    Ke, Qi
    Tisch, Roland M.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [48] The Interplay of Autoimmunity and Insulin Resistance in Type 1 Diabetes
    Nokoff, Natalie J.
    Rewers, Marian
    Green, Melanie Cree
    DISCOVERY MEDICINE, 2012, 13 (69) : 115 - 122
  • [49] Diabetic autoimmunity in infants and toddlers with type 1 diabetes
    Hathout, EH
    Racine, M
    Sharkey, J
    Mace, JW
    PEDIATRIC RESEARCH, 2000, 47 (04) : 131A - 131A
  • [50] Autoimmunity to tetraspanin-7 in type 1 diabetes
    Kerry A. McLaughlin
    Melissa A. Tombs
    Michael R. Christie
    Medical Microbiology and Immunology, 2020, 209 : 437 - 445